


Welcome and Introductions

Kathleen Moore, MD



Our Expert Panel



Kathleen Moore, MD
Stephenson Cancer Center,
University of Oklahoma



**Isabelle Ray-Coquard,
MD, PhD**
Centre Leon Bérard



Linda Duska, MD, MPH
Emily Couric Clinical Cancer
Center, UVA Health



Róisín O'Cearbhaill, MD
Memorial Sloan Kettering
Cancer Center

Disclosures

Faculty

Isabelle Ray-Coquard, MD, PhD

Honoraria (personal): Adaptimmune, Agenus, Amgen, AstraZeneca, BMS, Clovis, Daiichi Sankyo, Deciphera, Eisai, EQRx, GSK, MacroGenics, Merck Serono, Mersana, Novartis, Onxeo, Roche, Sutro Biopharma

Honoraria (institution): MSD (translational research)

Funding (institution): BMS

Principal investigator: PAOLA-1 (unrecompensed)

President: GINECO (unrecompensed)

Kathleen Moore, MD

AstraZeneca Pharmaceuticals, Aadi Bioscience, Aravive Inc, Alkermes, Blueprint Medicines, Clovis Oncology, Caris Life Sciences, DualityBio, Eisai Inc., Genentech—a member of Roche group, GSK, Hengrui Therapeutics Inc, ImmunoGen, InxMed, I-Mab, Janssen, Lilly, Mersana, Mereo BioPharma, Myriad Genetic Laboratories Inc, Merck, Novartis, Onconova Therapeutics Inc., OncXerna Therapeutics, Panavance Therapeutics, Regeneron Pharmaceuticals Inc., VBL Therapeutics, Verastem Oncology, Zentalis Pharmaceuticals.

AD: GOG-P and BOD for ASCO and GOG-F

Linda Duska, MD, MPH

Honoraria: Aadi Bioscience and Regeneron,

Fees (to institution): Merck

Editorial Board: British Journal of Obstetrics and Gynecology

Personal royalties: Writing expert content for UpToDate

Research funding (institution): Merck

Clinical trial grants (to institution): Genentech/Roche, AbbVie/(GOG 3005), Acrivon, Advaxis, Aduro BioTech, Alkermes, Blueprint, Constellation, Eisai, GSK/Novartis, Immunogen, Inovio, Iovance, Karyopharm, KSQ Therapeutics, Lycera, Merck, Morab, MorphoTek, Naveris, Nurix, OncoQuest, Pfizer, Syndax, Tesaro, Zentalis

Membership of data and safety monitoring committees: Agenus and Innovio (to institution)

Róisín O'Cearbhaill, MD

Consulting or Advisory Role: Bayer, ImmunoGen, Regeneron Pharmaceuticals, Inc., Seattle Genetics and Tesaro/GlaxoSmithKline, Miltenyi Biotec, 2seventy bio

Honoraria: MJH Life Sciences, Curio BioScience, OncLive/PER and GOG Foundation

Research funding (to institution): AbbVie/Stemcentrx, Alkermes, ArsenalBio, Atara Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen, GOG-F, Kite Pharma, Lyell Immunopharma, Ludwig Cancer Research, Marker Therapeutics, Merck, Regeneron Pharmaceuticals Inc., SELLAS Life Sciences Group, Syndax Pharmaceuticals, TCR2 Therapeutics, Lyell Immunopharma, Inc., and Tesaro/GSK.

Agenda

Topic	Presenter
Welcome and Introduction	Kathleen Moore, MD Stephenson Cancer Center, University of Oklahoma
ADC Opportunities in Ovarian Cancer	Isabelle Ray-Coquard, MD, PhD Centre Leon Bérard
Patient-Focused Treatment Quality of Life With ADCs: The ABCs of ADCs for Patient Care	Linda Duska, MD, MPH Emily Couric Clinical Cancer Center, UVA Health
Panel Discussion: Available Treatments and Most Active Target/Payload Combination	All Faculty (Moderator: Kathleen Moore, MD)
Important Advancements in Clinical Trial Development: How Lessons Learned Influence and Shape Future Opportunities	Róisín O'Cearbhaill, MD Memorial Sloan Kettering Cancer Center
Panel Discussion and Audience Q&A	All Faculty (Moderator: Kathleen Moore, MD)